Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial The Lancet Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug Topline data from REDEFINE 1 found CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss versus placebo in adults with obesity or overweight. https: t.co JA9E3FpCsN #ObesityManagement # Cagrilintide Research Peptide Information Peptpedia Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Were entering a new chapter in weight and metabolic health. While GLP 1s have been in the spotlight, researchers are finding that amylin agonists may offer similar levels of weight loss and were